EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial
Conditions: Type 2 Diabetes; Obesity Interventions: Other: Weight Management Program (WMP); Other: Traditional care; Drug: Phentermine / Topiramate Extended Release Oral Capsule; Drug: naltrexone/bupropion extended-release; Drug: liraglutide 3.0 mg; Drug: Orlistat Sponsor: The Cleveland Clinic Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 28, 2020 Category: Research Source Type: clinical trials
A Proof of Concept Trial in Overweight and Obese Patients, Investigating Effect of EMP16-02 on Body Weight (Primary)
Condition: Overweight or Obesity Interventions: Drug: EMP16-02 120 mg orlistat/40 mg acarbose; Drug: EMP16-02 150 mg orlistat/50 mg acarbose; Drug: Placebo Sponsors: Empros Pharma AB; Clinical Trial Consultants AB Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 21, 2020 Category: Research Source Type: clinical trials
